Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lamivudine/maraviroc/zidovudine

Next Previous
Drug Profile

Lamivudine/maraviroc/zidovudine

Alternative Names: GSK 2838510; Lamivudine/zidovudine/maraviroc; Maraviroc/lamivudine/zidovudine; Maraviroc/zidovudine/lamivudine; Zidovudine/lamivudine/maraviroc; Zidovudine/maraviroc/lamivudine

Latest Information Update: 02 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Antiretrovirals; Azides; Cyclohexanes; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules; Triazoles
  • Mechanism of Action CCR5 receptor antagonists; Nucleoside reverse transcriptase inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported HIV-1 infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-1-infections(In volunteers) in USA (PO, Tablet)
  • 31 Jan 2012 GlaxoSmithKline completes a Phase-I bioequivalence trial in HIV-1 infections (in volunteers) in USA (NCT01597648)
  • 01 Nov 2011 Phase-I clinical trials in HIV-1 infections (in volunteers) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top